Nmp4/CIZ suppresses the response of bone to anabolic parathyroid hormone by regulating both osteoblasts and osteoclasts

Calcified Tissue International

Volumn 89, Issue 1, 2011, Pages 74-89

  Childress, Paul ^a   Philip, Binu K ^a,d   Robling, Alexander G ^a,b   Bruzzaniti, Angela ^c   Kacena, Melissa A ^a,b   Bivi, Nicoletta ^a   Plotkin, Lilian I ^a   Heller, Aaron ^a,e   Bidwell, Joseph P ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Indiana University Purdue University Indianapolis   (United States)

^c INDIANA UNIVERSITY SCHOOL OF DENTISTRY   (United States)

^d BRISTOL MYERS SQUIBB   (United States)

^e KANSAS CITY UNIVERSITY OF MEDICINE AND BIOSCIENCES   (United States)

Author keywords

c fos; Ephrin; Fra 2; Osteocalcin; Osteoclastogenesis; Osteoporosis

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; ALKALINE PHOSPHATASE; BONE MORPHOGENETIC PROTEIN 2; CALCEIN; CARBOXY TERMINAL TELOPEPTIDE; CAS INTERACTING ZINC FINGER PROTEIN; COLLAGENASE 3; COLONY STIMULATING FACTOR 1; COLONY STIMULATING FACTOR RECEPTOR; EPHRIN; EPHRIN B2; LYMPHOID ENHANCER FACTOR 1; MITOGEN ACTIVATED PROTEIN KINASE 1; MONOCYTE CHEMOTACTIC PROTEIN 1; NUCLEAR MATRIX PROTEIN; NUCLEAR MATRIX PROTEIN 4; NUCLEAR RECEPTOR RELATED FACTOR 1; OSTEOCALCIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PARATHYROID HORMONE RECEPTOR 1; PARATHYROID HORMONE RELATED PROTEIN; PARATHYROID HORMONE[1-34]; PROTEIN BCL 2; PROTEIN C FOS; SOMATOMEDIN; TRANSCRIPTION FACTOR FRA 2; TRANSCRIPTION FACTOR JUND; TRANSCRIPTION FACTOR OSTERIX; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BONE MASS; BONE MINERAL; CANCELLOUS BONE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENOTYPE; MORPHOMETRICS; MOUSE; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOCLASTOGENESIS; OSTEOLYSIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SKELETON; TRABECULAR BONE;

ANIMALS; BONE DENSITY; BONE RESORPTION; HUMANS; MICE; MICE, KNOCKOUT; NUCLEAR MATRIX-ASSOCIATED PROTEINS; OSTEOBLASTS; OSTEOCLASTS; PARATHYROID HORMONE; TRANSCRIPTION FACTORS;

EID: 79959745238     PISSN: 0171967X     EISSN: 14320827     Source Type: Journal    
DOI: 10.1007/s00223-011-9496-y     Document Type: Article

References (38)

1. Stroup J, Kane MP, Abu-Baker AM (2008) Teriparatide in the treatment of osteoporosis. Am J Health Syst Pharm 65:532-539
2. Liu H, Michaud K, Nayak S, Karpf DB, Owens DK, Garber AM (2006) The cost-effectiveness of therapy with teriparatide and alendronate in women with severe osteoporosis. Arch Intern Med 166:1209-1217 (Pubitemid 43877630)
3. Childress P, Robling AG, Bidwell JP (2010) Nmp4/CIZ: road block at the intersection of PTH and load. Bone 46:259-266
4. Ahlström M, Lamberg-Allardt C (1997) Rapid protein kinase A - mediated activation of cyclic AMP-phosphodiesterase by parathyroid hormone in UMR-106 osteoblast-like cells. J Bone Miner Res 12:172-178 (Pubitemid 27086297)
5. Bellido T, Ali AA, Plotkin LI, Fu Q, Gubrij I, Roberson PK, Weinstein RS, O'Brien CA, Manolagas SC, Jilka RL (2003) Proteasomal degradation of Runx2 shortens parathyroid hormone- induced anti-apoptotic signaling in osteoblasts. A putative explanation for why intermittent administration is needed for bone anabolism. J Biol Chem 278:50259-50272 (Pubitemid 37548867)
6. Robling AG, Childress P, Yu J, Cotte J, Heller A, Philip BK, Bidwell JP (2009) Nmp4/CIZ suppresses parathyroid hormoneinduced increases in trabecular bone. J Cell Physiol 219:734-743
7. Thunyakitpisal P, Alvarez M, Tokunaga K, Onyia JE, Hock J, Ohashi N, Feister H, Rhodes SJ, Bidwell JP (2001) Cloning and functional analysis of a family of nuclear matrix transcription factors (NP/NMP4) that regulate type I collagen expression in osteoblasts. J Bone Miner Res 16:10-23 (Pubitemid 32046183)
8. Shah R, Alvarez M, Jones DR, Torrungruang K, Watt AJ, Selvamurugan N, Partridge NC, Quinn CO, Pavalko FM, Rhodes SJ, Bidwell JP (2004) Nmp4/CIZ regulation of matrix metalloproteinase 13 (MMP-13) response to parathyroid hormone in osteoblasts. Am J Physiol Endocrinol Metab 287:E289-E296 (Pubitemid 38943895)
9. Philip BK, Childress PJ, Robling AG, Heller A, Nawroth PP, Bierhaus A, Bidwell JP (2010) RAGE supports parathyroid hormone- induced gains in femoral trabecular bone. Am J Physiol Endocrinol Metab 298:E714-E725
10. Chung DJ, Castro CH, Watkins M, Stains JP, Chung MY, Szejnfeld VL, Willecke K, Theis M, Civitelli R (2006) Low peak bone mass and attenuated anabolic response to parathyroid hormone in mice with an osteoblast-specific deletion of connexin43. J Cell Sci 119:4187-4198 (Pubitemid 44774025)
11. Cheng S, Sipilä S, Taaffe DR, Puolakka J, Suominen H (2002) Change in bone mass distribution induced by hormone replacement therapy and high-impact physical exercise in post-menopausal women. Bone 31:126-135 (Pubitemid 34754438)
12. Goossens K, Van Poucke M, Van Soom A, Vandesompele J, Van Zeveren A, Peelman LJ (2005) Selection of reference genes for quantitative real-time PCR in bovine preimplantation embryos. BMC Dev Biol 5:27
13. Zhang X, Ding L, Sandford AJ (2005) Selection of reference genes for gene expression studies in human neutrophils by realtime PCR. BMC Mol Biol 6:4
14. Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR (1987) Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 2:595-610
15. O'Brien CA, Plotkin LI, Galli C, Goellner JJ, Gortazar AR, Allen MR, Robling AG, Bouxsein M, Schipani E, Turner CH, Jilka RL, Weinstein RS, Manolagas SC, Bellido T (2008) Control of bone mass and remodeling by PTH receptor signaling in osteocytes. PLoS One 3:e2942
16. Tanaka S, Amling M, Neff L, Peyman A, Uhlmann E, Levy JB, Baron R (1996) c-Cbl is downstream of c-Src in a signalling pathway necessary for bone resorption. Nature 383:528-531 (Pubitemid 26346179)
17. Iida-Klein A, Zhou H, Lu SS, Levine LR, Ducayen-Knowles M, Dempster DW, Nieves J, Lindsay R (2002) Anabolic action of parathyroid hormone is skeletal site specific at the tissue and cellular levels in mice. J Bone Miner Res 17:808-816 (Pubitemid 34441897)
18. Morinobu M, Nakamoto T, Hino K, Tsuji K, Shen ZJ, Nakashima K, Nifuji A, Yamamoto H, Hirai H, Noda M (2005) The nucleocytoplasmic shuttling protein CIZ reduces adult bone mass by inhibiting bone morphogenetic protein-induced bone formation. J Exp Med 201:961-970 (Pubitemid 40524465)
19. Karreth F, Hoebertz A, Scheuch H, Eferl R, Wagner EF (2004) The AP1 transcription factor Fra2 is required for efficient cartilage development. Development 131:5717-5725 (Pubitemid 39625214)
20. Bozec A, Bakiri L, Hoebertz A, Eferl R, Schilling AF, Komnenovic V, Scheuch H, Priemel M, Stewart CL, Amling M, Wagner EF (2008) Osteoclast size is controlled by Fra-2 through LIF/LIFreceptor signalling and hypoxia. Nature 454:221-225 (Pubitemid 351969891)
21. Liang JD, Hock JM, Sandusky GE, Santerre RF, Onyia JE (1999) Immunohistochemical localization of selected early response genes expressed in trabecular bone of young rats given hPTH 1-34. Calcif Tissue Int 65:369-373 (Pubitemid 29514074)
22. Qin L, Raggatt LJ, Partridge NC (2004) Parathyroid hormone: a double-edged sword for bone metabolism. Trends Endocrinol Metab 15:60-65 (Pubitemid 38253007)
23. D'Alonzo RC, Selvamurugan N, Karsenty G, Partridge NC (2002) Physical interaction of the activator protein-1 factors c-Fos and c-Jun with Cbfa1 for collagenase-3 promoter activation. J Biol Chem 277:816-822 (Pubitemid 34952122)
24. Nervina JM, Magyar CE, Pirih FQ, Tetradis S (2006) PGC- 1alpha is induced by parathyroid hormone and coactivates Nurr1- mediated promoter activity in osteoblasts. Bone 39:1018-1025 (Pubitemid 44528369)
25. Qin L, Li X, Ko JK, Partridge NC (2005) Parathyroid hormone uses multiple mechanisms to arrest the cell cycle progression of osteoblastic cells from G1 to S phase. J Biol Chem 280:3104-3111 (Pubitemid 40189421)
26. Wagner EF (2010) Bone development and inflammatory disease is regulated by AP-1 (Fos/Jun). Ann Rheum Dis 69(Suppl 1):i86-i88
27. Tobimatsu T, Kaji H, Sowa H, Naito J, Canaff L, Hendy GN, Sugimoto T, Chihara K (2006) Parathyroid hormone increases beta-catenin levels through Smad3 in mouse osteoblastic cells. Endocrinology 147(5):2583-2590
28. Boyle WJ, Simonet WS, Lacey DL (2003) Osteoclast differentiation and activation. Nature 423:337-342 (Pubitemid 40852708)
29. Takayanagi H (2007) The role of NFAT in osteoclast formation. Ann N Y Acad Sci 1116:227-237
30. Takayanagi H, Kim S, Matsuo K, Suzuki H, Suzuki T, Sato K, Yokochi T, Oda H, Nakamura K, Ida N, Wagner EF, Taniguchi T (2002) RANKL maintains bone homeostasis through c-fos-dependent induction of interferon-beta. Nature 416:744-749 (Pubitemid 34429151)
31. Fu Q, Jilka RL, Manolagas SC, O'Brien CA (2002) Parathyroid hormone stimulates receptor activator of NFkappaB ligand and inhibits osteoprotegerin expression via protein kinase A activation of cAMP-response element-binding protein. J Biol Chem 277:48868-48875 (Pubitemid 35470855)
32. Li X, Qin L, Bergenstock M, Bevelock LM, Novack DV, Partridge NC (2007) Parathyroid hormone stimulates osteoblastic expression of MCP-1 to recruit and increase the fusion of pre/ osteoclasts. J Biol Chem 282:33098-33106 (Pubitemid 350159306)
33. 2+-NFATc1 signaling is an essential axis of osteoclast differentiation. Immunol Rev 231:241-256
34. -/- mice. J Bone Miner Res 24:1586-1597
35. Zhao C, Irie N, Takada Y, Shimoda K, Miyamoto T, Nishiwaki T, Suda T, Matsuo K (2006) Bidirectional ephrinB2-EphB4 signaling controls bone homeostasis. Cell Metab 4:111-121 (Pubitemid 44138718)
36. Koh AJ, Demiralp B, Neiva KG, Hooten J, Nohutcu RM, Shim H, Datta NS, Taichman RS, McCauley LK (2005) Cells of the osteoclast lineage as mediators of the anabolic actions of parathyroid hormone in bone. Endocrinology 146(11):4584-4596 (Pubitemid 41446596)
37. Allen MR, Burr DB (2006) Parathyroid hormone and bone biomechanics. Clin Rev Bone Miner Metab 4:259-268 (Pubitemid 46568224)
38. Krane SM (2005) Identifying genes that regulate bone remodeling as potential therapeutic targets. J Exp Med 201:841-843